Centessa Pharmaceuticals Analyst Ratings
Centessa Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/15/2023 | -24.47% | Goldman Sachs | $4.5 → $5 | Maintains | Neutral |
| 07/25/2023 | 126.59% | BMO Capital | $11 → $15 | Maintains | Outperform |
| 06/21/2023 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 06/12/2023 | 35.95% | Guggenheim | → $9 | Initiates Coverage On | → Buy |
| 05/15/2023 | -32.02% | Goldman Sachs | $4 → $4.5 | Maintains | Neutral |
| 03/17/2023 | -9.37% | SVB Leerink | → $6 | Initiates Coverage On | → Outperform |
| 01/24/2023 | -39.58% | Morgan Stanley | $5 → $4 | Maintains | Underweight |
| 08/12/2022 | -24.47% | Morgan Stanley | $10 → $5 | Downgrades | Overweight → Underweight |
| 08/11/2022 | 66.16% | BMO Capital | $19 → $11 | Maintains | Outperform |
| 08/11/2022 | -39.58% | Goldman Sachs | $5 → $4 | Maintains | Neutral |
| 07/15/2022 | 51.06% | Morgan Stanley | $15 → $10 | Maintains | Overweight |
| 06/17/2022 | 187.01% | BMO Capital | → $19 | Initiates Coverage On | → Outperform |
| 05/24/2022 | 126.59% | Morgan Stanley | $19 → $15 | Maintains | Overweight |
| 05/24/2022 | 20.85% | Goldman Sachs | $12 → $8 | Maintains | Neutral |
| 04/05/2022 | 187.01% | Morgan Stanley | $20 → $19 | Maintains | Overweight |
| 06/23/2021 | 458.91% | Morgan Stanley | → $37 | Initiates Coverage On | → Overweight |
| 06/22/2021 | 534.44% | Goldman Sachs | → $42 | Initiates Coverage On | → Buy |
| 06/22/2021 | 458.91% | Morgan Stanley | → $37 | Initiates Coverage On | → Overweight |
| 06/22/2021 | 428.7% | Jefferies | → $35 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年08月15日 | -24.47% | 高盛 | $4.5→$5 | 维护 | 中性 |
| 07/25/2023 | 126.59% | 蒙特利尔银行资本 | $11→$15 | 维护 | 跑赢大盘 |
| 2023年6月21日 | - | Evercore ISI集团 | 开始承保 | →跑赢大盘 | |
| 2023/06/12 | 35.95% | 古根海姆 | →$9 | 开始承保 | →购买 |
| 2023年05月15日 | -32.02% | 高盛 | $4→$4.5 | 维护 | 中性 |
| 03/17/2023 | -9.37% | SVB Leerink | →$6 | 开始承保 | →跑赢大盘 |
| 01/24/2023 | -39.58% | 摩根士丹利 | $5→$4 | 维护 | 体重不足 |
| 2022年08月12日 | -24.47% | 摩根士丹利 | $10→$5 | 评级下调 | 增持→减持 |
| 2022年08月11日 | 66.16% | 蒙特利尔银行资本 | $19→$11 | 维护 | 跑赢大盘 |
| 2022年08月11日 | -39.58% | 高盛 | $5→$4 | 维护 | 中性 |
| 07/15/2022 | 51.06% | 摩根士丹利 | $15→$10 | 维护 | 超重 |
| 06/17/2022 | 187.01% | 蒙特利尔银行资本 | →$19 | 开始承保 | →跑赢大盘 |
| 2022年05月24日 | 126.59% | 摩根士丹利 | $19→$15 | 维护 | 超重 |
| 2022年05月24日 | 20.85% | 高盛 | $12→$8 | 维护 | 中性 |
| 04/05/2022 | 187.01% | 摩根士丹利 | $20→$19 | 维护 | 超重 |
| 2021/06/23 | 458.91% | 摩根士丹利 | →$37 | 开始承保 | →超重 |
| 2021/06/22 | 534.44% | 高盛 | →$42 | 开始承保 | →购买 |
| 2021/06/22 | 458.91% | 摩根士丹利 | →$37 | 开始承保 | →超重 |
| 2021/06/22 | 428.7% | 杰富瑞 | →$35 | 开始承保 | →购买 |
What is the target price for Centessa Pharmaceuticals (CNTA)?
Centessa PharmPharmticals(CNTA)的目标价是多少？
The latest price target for Centessa Pharmaceuticals (NASDAQ: CNTA) was reported by Goldman Sachs on August 15, 2023. The analyst firm set a price target for $5.00 expecting CNTA to fall to within 12 months (a possible -24.47% downside). 7 analyst firms have reported ratings in the last year.
高盛于2023年8月15日报告了Centessa PharmPharmticals(纳斯达克代码：CNTA)的最新目标价。这家分析公司将目标价定为5美元，预计CNTA将在12个月内下跌(可能下跌24.47%)。去年有7家分析公司公布了评级。
What is the most recent analyst rating for Centessa Pharmaceuticals (CNTA)?
Centessa PharmPharmticals(CNTA)的最新分析师评级是什么？
The latest analyst rating for Centessa Pharmaceuticals (NASDAQ: CNTA) was provided by Goldman Sachs, and Centessa Pharmaceuticals maintained their neutral rating.
高盛提供对Centessa PharmPharmticals(纳斯达克代码：CNTA)的最新分析师评级，Centessa PharmPharmticals维持中性评级。
When is the next analyst rating going to be posted or updated for Centessa Pharmaceuticals (CNTA)?
Centessa PharmPharmticals(CNTA)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Centessa Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Centessa Pharmaceuticals was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Centessa PharmPharmticals的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Centessa制药的上一次评级是在2023年8月15日提交的，所以你应该预计下一次评级将在2024年8月15日左右的某个时候提供。
Is the Analyst Rating Centessa Pharmaceuticals (CNTA) correct?
分析师对Centessa PharmPharmticals(CNTA)的评级正确吗？
While ratings are subjective and will change, the latest Centessa Pharmaceuticals (CNTA) rating was a maintained with a price target of $4.50 to $5.00. The current price Centessa Pharmaceuticals (CNTA) is trading at is $6.62, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但Centessa PharmPharmticals(CNTA)的最新评级保持不变，目标价在4.50美元至5.00美元之间。Centessa PharmPharmticals(CNTA)目前的交易价格为6.62美元，超出了分析师的预测区间。